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N-linked oligosaccharides obtained from total serum of mice with implanted head and neck
tumors were analyzed and compared with those from control samples of healthy mice.
Methods used include a combination of a derivatization procedure with phenylhydrazine
(PHN) and analysis by matrix-assisted laser desorption/ionization mass spectrometry
(MALDI-MS). Oligosaccharides were enzymatically released from total serum with PNGaseF
and purified by high-performance liquid chromatography (HPLC) on a reversed-phase
column. Mass spectra contained ion peaks of labeled oligosaccharides and MS/MS experi-
ments provided useful data for the structural elucidation of these compounds. More than 40
N-glycans with compositions characteristic of high-mannose, hybrid, complex, neutral, and
sialylated structures were identified in the serum of tumoral mice. Significant differences
between samples were observed with respect to the abundances of high mannose and hybrid
glycans. These oligosaccharides showed higher relative intensities in the spectra obtained from
the cancer sera. Complex sialylated oligosaccharides had similar abundances in both types of
sera, with the exception of fucosylated biantennary disialylated oligosaccharide, which was
mostly detected with lower abundance in control samples. In the MALDI spectra, several
minor species corresponded to uncommon carbohydrates. These structures have been inves-
tigated in detail by MS/MS. Among these novel glycoforms, a few sialylated oligosaccharides
without a free reducing end were identified. Also, glycans with an extra 60 u were observed
and likely feature the presence of a 2-acetamido-2-deoxyoctose residue attached on antennae
of 3- or 6-linked mannose. (J Am Soc Mass Spectrom 2008, 19, 671–685) © 2008 American
Society for Mass SpectrometryThe importance of protein glycosylation as onemode of post-translational modification is re-flected by the large number of glycosylated pro-
teins employed by organisms in a myriad of biological
processes [1]. It has been recognized that altered glyco-
sylation is an universal feature of living cells and
several studies have demonstrated that the changes in
cellular glycosylation profiles can be also related to
aggressive cancer cell behavior, such as tumor cell
invasion and metastasis [2–8]. As cancer cells can
produce oligosaccharides that are significantly different
from those in normal cells, comparative studies be-
tween glycoprotein carbohydrates produced by malig-
nant cells and normal cells may provide useful infor-
mation for diagnosis, prognosis, and immunotherapy of
tumors [9].
Mass spectrometry (MS) has been used extensively
as the most sensitive method for the analysis of carbo-
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doi:10.1016/j.jasms.2008.01.016hydrate molecules [10–14]. Moreover, modern MS in-
struments allow the measurement of unseparated mix-
tures, and make possible the identification of trace
amounts of glycans in biological materials [15]. None-
theless, biochemical analysis of carbohydrates is gener-
ally complicated, not only because of their lower con-
centration relative to with proteins, but also because of
the structural diversity of molecules, anomericity, link-
age positions, and branching patterns of monosacchar-
ides. Moreover, carboxylic groups cause sialylated oli-
gosaccharides to ionize with less efficiency than neutral
oligosaccharides, making MS analysis of glycans more
difficult in the positive ion mode [16]. Neutral oligosac-
charides can be separated from acidic ones by various
techniques before analysis [17, 18], or to chemically
modify the carboxyl group by methods such as methyl
esterification [19], permethylation [20], or amidation [21].
Recently, mass spectrometric approaches have be-
come popular for the screening of oligosaccharide pro-
files in blood from assorted sources. Several studies
have demonstrated changes in the glycosylation pro-
files of glycoproteins in sera associated with a variety of
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672 LATTOVÁ ET AL. J Am Soc Mass Spectrom 2008, 19, 671–685diseases. Among them, serum obtained from wood-
chucks diagnosed with hepatocellular carcinoma had
higher levels of oligosaccharides with core -1,6-linked
fucose [22]. Serum of patients with cirrhosis showed a
heterogeneous distribution of N-glycans compared
with healthy samples [23]. In a study on human pan-
creatic cancer, serum samples contained N-glycans with
increased fucosylation and sialylation relative to those
from healthy individuals [24]. Samples in the study of
ovarian cancer patients also showed a number of neu-
tral oligosaccharides that appeared related to cancer
[25]. Despite intense research efforts, many times the
findings are relevant only to the particular biological
material on which the analysis was performed. Each
Figure 1. Representative positive MALDI-QqT
total mouse serum. Samples were first digested
released with PNGaseF and labeled with PHN: (
healthy serum; (c) Fraction 2 from tumor serum;
see Tables 1 and 2. Symbols: (filled triangle) Fuc
GlcNAc; (filled diamond) NeuGc; *oligosacch
oligosaccharides with a 60 u mass increment.approach for preparing samples has some advantagesand disadvantages, especially regarding the analysis of
tissue or blood. Consequently for most diseases, includ-
ing cancer ailments, the facts and links still need to be
thoroughly understood and validated by obtaining as
much information as possible to replicate the findings.
The original aim of this study was to analyze oligo-
saccharides enzymatically released from total serum of
nude mice with implanted head and neck tumors. The
term “head and neck cancer” generally refers to malig-
nant growths that arise from the surface epithelium of
the upper aerodigestive tract. About 50,000 cases of
head and neck cancers are diagnosed in the USA and
Canada every year with 25% of these patients even-
tually dying from this disease [26]. Squamous cell
ass spectra recorded from HPLC fractions of
trypsin/chymotrypsin. Oligosaccharides were
ction 1 from healthy serum; (b) Fraction 2 from
action 3 obtained from tumor serum. For details
ed circle) Gal; (open circle) Man; (filled square)
s with dehydrated monosaccharide residue;OF m
with
a) Fra
(d) Fr
; (fill
aridecarcinomas (SCC) are the most common malignant
. Co
673J Am Soc Mass Spectrom 2008, 19, 671–685 N-LINKED OLIGOSACCHARIDES AND UNCOMMON GLYCOFORMhistology in the head and neck region. SCC of the upper
aerodigestive tract is one of the leading causes of death
worldwide. Previously it was demonstrated that the
sera of patients with head and neck carcinomas show
tumor-size-dependent elevations of serum ganglio-
sides [27]. In view of the role of glycosylation inhib-
itors, it was postulated that chemical manipulation of
glycosylation can be a useful therapeutic strategy for
successful chemotherapy against head and neck can-
cer [28].
In our previous recent articles we introduced devel-
opment phenylhydrazine (PHN) derivatization for la-
beling oligosaccharides from commercial sources [29,
32]. The present study for the first time demonstrates
application of this method for mass spectrometric anal-
yses of carbohydrates from real complex biological
material. Oligosaccharides obtained from the serum of
cancerous mice were tagged with PHN and compared
Figure 1also with profiles of oligosaccharides from control sera.For purification of samples, reversed-phase high-per-
formance liquid chromatography (RP-HPLC) was em-
ployed and all glycans were analyzed by matrix-as-
sisted laser desorption ionization (MALDI) mass
spectrometry. Acidic N-glycans were characterized in
one step together with neutral oligosaccharides, with-
out additional procedures to eliminate sialylated resi-
dues. Particular attention was paid to some oligosac-
charide of uncommon composition, described for the
first time in this study. Structures for these forms are
suggested according to highly reproducible tandem MS
(MS/MS) data.
Experimental
Materials and Reagents
Serum samples for this project were obtained from eight
CD-1 nude mice, which were injected with human head
ntinuedand neck cancer cells (FaDu cell line) in the right flank.
674 LATTOVÁ ET AL. J Am Soc Mass Spectrom 2008, 19, 671–685Table 1. Structures of derivatized N-glycans with masses  1000 Da recorded from mice serum on the MALDI-QqTOF mass
spectrometer in positive mode. Stars refer to ion abundances
Observed m/z Structure
Serum
Cancerous Healthy
1226.4 [MNa]
PHN
MS/MS
Yes(*) Yes(*)
1347.5 [MNa]
PHN MS/MS
Yes(***) No
1388.5 [MNa]
PHN
MS/MS
Yes(*) Yes(*)
1509.5 [MNa]
PHN
MS/MS
Yes(***) No
1534.5 [MNa]
PHN
calcul.
Yes(*) Yes(*)
1550.5 [MNa]
PHN MS/MS
Yes() No
1555.5 [MNa] PHN
calcul.
Yes(*) No
1575.5 [MNa]
PHN
calcul.
Yes(*) No
1591.6 [MNa]
PHN
MS/MS
Yes(*) Yes(*)
1656.6 [MNa]
PHN
calcul.
Yes(*) No
1671.6 [MNa]
PHN
MS/MS
Yes(*) No
1695.6 [MNa]
1717.6 [M–H2Na]
PHN
calcul.
Yes(*) Yes(*)
1712.6 [MNa]
PHN
MS/MS
Yes() No
1737.6 [MNa]
PHN
calcul.
Yes(*) No
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Observed m/z Structure
Serum
Cancerous Healthy
1753.6 [MNa]
PHN
MS/MS
Yes(***) Yes(***)
1778.6 [MNa]
PHN
calcul.
Yes(*) Yes(*)
1841.6 [MNa]
PHN
calcul.
Yes(*) Yes(*)
1857.6 [MNa]
1879.6 [M–H2Na]
PHN
MS/MS
Yes(***) No
1899.7 [MNa]
PHN
MS/MS
Yes() Yes()
1920.6 [M–H2Na]
PHN
calcul.
Yes() No
2019.7 [MNa]
2041.7 [M–H2Na] PHN
MS/MS
Yes() No
2060.7 [MNa]
2082.7 [M-H2Na] PHN MS/MS
Yes(***) Yes(***)
2066.7 [M-H2Na]
PHN
calcul.
Yes(*) Yes(*)
2118.7 [MNa]
PHN
calcul.
Yes(*) Yes(*)
2182.7 [MNa]
PHN
calcul.
Yes(*) No
2206.8 [MNa]
2228.7 [M–H2Na] PHN
MS/MS
Yes(***) Yes(*)
2367.8 [MNa]
2389.8 [M–H2Na]
2411.8 [M–2H3Na]
PHN
MS/MS
Yes(***) Yes(***)
2409.9 [MNa]
2431.8 [M–H2Na]
2513.9 [MNa]
2535.8 [M–H2Na]
2557.8 [M–2H3Na]
PHN
calcul.
PHN
MS/MS
Yes(*)
Yes(***)
Yes(*)
Yes(*)
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Observed m/z Structure
Serum
Cancerous Healthy
2571.0 [MNa]
PHN
calcul.
Yes(*) Yes(*)
2573.8 [M–2H3Na]
PHN
MS/MS
Yes(*) No
2674.7 [MNa]
2696.7 [M–H2Na] PHN
MS/MS
Yes(***) Yes(***)
2716.9 [MNa]
PHN
calcul.
Yes(*) Yes(*)
2732.8 [MNa]
PHN
PHN
MS/MS
Yes() Yes()
2821.0 [MNa]
2886.9 [M–3H4Na] PHN
calcul.
Yes() Yes()
3039.8 [MNa]
3061.9 [M–H2Na]
3105.9 [M–3H4Na]
PHN
PHN
MS/MS
Yes(***) Yes(***)
3185.9 [MNa]
PHN
PHN
MS/MS
Yes() Yes()
3347.1 [MNa]
PHN
MS/MS
Yes() Yes()
3493.2 [MNa]
PHN
MS/MS
Yes(*) Yes(*)
3712.3 [MNa]
PHN
MS/MS
Yes(*) Yes(*)
Key symbols:  GlcNAc;  Gal; Œ Man;‘ Fuc;  NeuGc;
***abundant,
*minor.
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reached a size between 6 and 10 mm in longest diam-
eter. Control sera were obtained from five healthy mice
of the same type.
Phenylhydrazine (PHN) and 2,5-dihydroxybenzoic
acid (DHB) were obtained from Sigma (St. Louis, MO).
Sequencing grade trypsin (spec. activity: 18 800 u/mg)
was obtained from Promega (Madison, WI), chymo-
trypsin and pronase from Sigma. Peptide-N-glycosi-
dase F (PNGase F; supplied glycerol free) deglycosyla-
tion kits were purchased from Prozyme (San Leandro,
CA). Solvents (acetonitrile, ethanol) were HPLC-grade
and obtained from Fisher Scientific (Fair Lawn, NJ).
HPLC-grade water was obtained with a Milli-Q plus TOC
water purification system (Millipore, Bedford, MA).
Release of N-Linked Oligosaccharides from Serum
Mouse serum (50 L) was first denatured at 95 °C for 5
min. After cooling to room temperature, serum was
digested with trypsin (10 L) and chymotrypsin (50 g
dissolved in 20 mM ammonium bicarbonate) at 37 °C
for 24 h. Then, PNGase F enzyme (5 L; 10 u) was
added and the total mixture was again incubated at
37 °C for 24 h. Next, pronase solution (20 g dissolved
in 20 L of 25 mM ammonium bicarbonate) was added
to the digested serum and again incubation proceeded
for 10 h at 37 °C. During the incubation time, the
reaction sample was mixed occasionally.
Derivatization of Oligosaccharides in Total
Digested Serum
After enzymatic digestions total serum was heated with
phenylhydrazine (5 L) at 70 °C for 1 h (mixed period-
ically during incubation) [29].
RP-HPLC Fractionation of the Treated Serum
The samples of digested mice sera (native and derivat-
ized) were fractionated and purified on a System Gold
HPLC chromatograph equipped with a System Gold
166 UV Detector and 32-Karat software (Beckman-
Coulter, Canada, ON, Canada). For RP-HPLC, an ana-
lytical column Vydac 218 TP54 C18, 300-Å pore size,
0.46 cm  25 cm (Separation Group, Hesperia, CA) was
used. The chromatograph was equipped with a Rheo-
dyne injector (5 L loop). The samples were eluted
with 5% ACN in water as Solvent A, and 90% ACN in
0.1% TFA as Solvent B at a flow rate of 0.5 mL/min.
An elution gradient was applied from 5% to 70%
ACN over 30 min. UV detection was performed at 245
nm. Fractions were collected manually and concen-
trated in vacuo. Then 30% ACN in water (5 L) was
added to each dried fraction, mixed, and used for MS
analysis.MALDI-Mass Spectrometric Analysis
The spots from individual HPLC-fractions were ana-
lyzed by MALDI mass spectrometry (MS) and tandem
mass spectrometry (MS/MS) on the Manitoba/SCIEX
prototype quadrupole-quadrupole-TOF (QqTOF) mass
spectrometer [30]. In this instrument, ions are generated
irradiation of the sample with photon pulses from a 20
Hz nitrogen laser (VCL 337ND; Spectra-Physics, Moun-
tain View, CA) with 300 mJ energy per pulse. Parent
ions are selected in Q1 after cooling, after which they
are broken upon q2 by collisional-induced dissociation
(CID) at low-energy. The collisional energy for each
precursor ion m/z value was determined by applying
a well-defined accelerating voltage at the entrance of
the Q2 and values were around 50 V per 1000 Da. The
resulting product ions were measured in the TOF
analyzer. Orthogonal injection of ions from the quad-
rupole into the TOF section routinely produces a
mass resolving power of 10,000FWHM and accu-
racy within a few mDa, in both MS and MS/MS
modes.
A saturated matrix solution of 2,5-dihydroxybenzoic
acid (DHB) in acetonitrile:water (1:1) was deposited
onto the stainless steel MALDI target and analyte
solution (1 L) was spotted onto the dried matrix. Then,
before each spot dried completely, PHN solution was
spotted (0.5 L; 3 L of PHN reagent diluted in 12 L
of deionized water and 3 L of ACN) and samples were
left to dry at 37 °C (30 min). MS/MS spectra of
oligosaccharides were interpreted manually and de-
tected structures of common N-glycan were compared
with compositions described in previous studies [31–
33]. For the assignment of all oligosaccharide fragment
ions, the general nomenclature established by Domon
and Costello was followed [34].
Results and Discussion
Isolation of N-Linked Oligosaccharides from Serum
Serum samples obtained from cancerous and healthy
mice were first digested with trypsin/chymotrypsin
and deglycosylated directly without previous purifica-
tion from salts or other small components. An addi-
tional use of pronase allowed the cleavage of large
tryptic peptides/glycopeptides into small species. The
enzymatically digested sample was treated with PHN
and 10 L of the whole derivatized serum was then
purified by HPLC on a reversed-phase column. The
HPLC elution conditions used allowed pooling of oli-
gosaccharides (as intended) rather than complete sepa-
ration of these compounds. HPLC fractions obtained
within 10 min were evaporated and spotted with PHN
solution (see the Experimental section) to enhance the
oligosaccharide ion signals and suppress peaks of pep-
tides present in the mixture [35]. The same separation
procedure was applied for underivatized serum (serum
fractionated directly after enzymatic digestions without
678 LATTOVÁ ET AL. J Am Soc Mass Spectrom 2008, 19, 671–685previous PHN oligosaccharides derivatization). Frac-
tions were analyzed in both their native form and after
adding PHN solution (oligosaccharides were collected
within early fractions, 2.5–4 min). This variant of the
procedure was more suitable for pooling oligosaccha-
rides with three and more sialic acids on the antennae.
Generally, three fractions of oligosaccharides were
obtained (eluted by 10% ACN). The first fraction was
copious in oligosaccharides with three and more sialic
acids on the nonreducing chains. The composition was
very comparable in both types of serum (Figure 1a). The
second fraction (Figure 1b and c) contained abundant
neutral complex, galactosylated and mono/disialylated
structures. High-mannose glycans (m/z 1347.5, 1509.5,
1671.6) were observed in the spectra recorded from the
cancer sera (Figure 1d). Peaks observed in all spectra as
N-linked glycans and identified in both types of sera are
listed in Table 1. Typically, all neutral glycans produced
only [M  Na] ions. Sialylated oligosaccharides pro-
vided additional sodiated [M  (n  1)H  nNa] ions
depending on the (n  1) number of sialic acid residues
in the molecule. Multisodiated ions provided more
complicated MS/MS fragmentation patterns, however,
produced fragment ions containing the acidic residues,
important for determination of sialic acid position in the
molecule.
Furthermore, we observed peaks that according to
their m/z values were not consistent with typical oligo-
saccharide compositions. On the basis of MALDI-
MS/MS analyses, we found that these peaks corre-
sponded also to carbohydrate structures containing
noncharacteristic residues.
MALDI-MS/MS Characterization of N-Linked
Glycans
To verify the composition and obtain structural infor-
mation about oligosaccharide peaks observed in direct
mass spectra, a number of ions were subjected to
tandem analysis. Some structures of interest are con-
cisely discussed below.
High-mannose glycans. The abundant precursor ions
detected at m/z 1347.5, 1509.5, and 1671.6 (Figure 1d)
produced identical MS/MS fragmentation patterns. B,
C-fragment ions resulted from the loss of chitobiose
core and were consistent with a composition of high-
mannose glycans (Figure 2a). The loss of 3-positioned
hexose(s) from these fragment ions appeared at m/z
671.2 (B3/Y3). These ions underwent the characteristic
subsequent loss of water detected at m/z 653.2 [31, 32].
A-cross-ring cleavage ions of the reducing terminal
GlcNAc (m/z 1069.4, 1258.5, 1318.5) were consistent
with the cleavage of the chitobiose core.
Hybrid glycans. The glycans detected at m/z 1550.5 and
1712.7 in cancer sera ([MNa] parent ions, Figure 1c),
could be recognized as hybrid-type structures. B/Y-ions observed at m/z 671.2 and 653.5 were consistent
with the loss of chitobiose core and monosaccharide
residues from the 3-linked arm of the core mannose
(Figure 2b). Fragment ions at m/z 833.3 corresponding
to a (Hex)5 residue were produced from B4 (C4) ions by
loss of 162 and 203 u.
Sialylated glycans. The PHN-glycan detected at m/z
2041 as [M  H  2Na] was consistent again with a
not very common hybrid structure (described above)
in which sialic acid is linked to galactose on the 3-arm
(Figure 3a). Y6 fragment ions at m/z 1712.5 corre-
sponded to the loss of a single neuraminic acid (307
u). Disodiated C4 fragment ions detected at m/z 897.2
were consistent with the N-glycolyl-neuraminic acid
linked to galactose on the 3-antenna. PHN-oligosac-
charides with [M  Na] ions at m/z 2206.7 (Table 1)
corresponded to a mono sialylated structure with
fucose linked at the labeled GlcNAc-fragment ions
detected at m/z 1771.6 (B6), 1787.6 (C6), and 1584.5
(C5). Disodiated precursors at m/z 2228.7 ([M  H 
2Na]) produced cross-ring cleavage ions at m/z
1831.5 (2,4A7), consistent with fucose being linked at
the 6-position of the reducing-terminal GlcNAc resi-
due. The same type of fucosylation was found in the
neutral analog of this glycan with parent ions at m/z
1899.8 (2,4A7 cross-ring ions appeared at m/z 1502.6).
Disialylated oligosaccharides at m/z 2513.9 ([M 
Na]) produced fragment ions again consistent with
the presence of fucose at the reducing-terminus. In
the spectrum of multisodiated [M  2H  3Na]
parent ions (m/z at 2557.9), 2,4A7 cross-ring cleavages
were observed at m/z 2160.5, consistent with fucose
being linked to the 6-position of the labeled core
GlcNAc residue. In the MS spectra of both types of
sera, abundant [M  Na] peaks detected at m/z
2674.9 and [M  H  2Na] at m/z 2696.9 indicated a
trisialylated biantennary structure (Figure 3b). The
loss of three sialic acids produced abundant fragment
ions at m/z 1753.7. The cross-ring 1,5X4 fragments from
the 6-arm (m/z 1891.6) indicated two sialic acids
linked at the 3-arm. The MS/MS spectrum recorded
for precursor [M  Na] ions at m/z 3039.8 corre-
sponded to a triantennary oligosaccharide with sialic
acid on each arm. This structure was also consistent
with [M  Na] ions detected at m/z 3185.9 indicating
the presence of fucose (Figure 3c). Fragmentation of
parent ions at m/z 3347.1 was consistent with a
triantennary glycan as described above at m/z 3039.8
in the addition of sialic acid more (four sialic acid
moieties; Table 1). The Z3 fragment ions detected at
m/z 2190.8 corresponded to the loss of
(SA)2GalGlcNAcMan from the 3-arm of the core
mannose. No fragment ions were produced to sup-
port the presence of two sialic acids on one of the
6-arms.
679J Am Soc Mass Spectrom 2008, 19, 671–685 N-LINKED OLIGOSACCHARIDES AND UNCOMMON GLYCOFORMMALDI-MS/MS Characterization of Uncommon
Glycoforms
Peaks observed at m/z 1200.4, 1362.5, 1565.6, 1727.7, and
2034.7 (Table 2) were assigned as [M  H] ions of
sialylated oligosaccharides. Characteristic of these spe-
cies was the absence of reducing terminus (resistance to
PHN-derivatization signaled the absence of free car-
bonyl reducing-terminus). Instead, the dehydrated form
of monosaccharide residue terminated this unusual
glycan. These nonderivatizable saccharides produced
isobaric fragment ions, which resulted in complicated
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Figure 2. MALDI-MS/MS spectra of glycans re
sera, precursor ions at m/z: (a) 1509.6 [M  Na]
For symbols see Figure 1.ambiguous fragmentations for determination struc-tures. Generally, the loss of sialic acid (307 u) appeared
as Y-type fragment ions comprised of hexose and
N-acetylhexosamine residues (Figure 4). In all spectra
the abundant fragment ions at m/z 673.23 were consistent
with B-type ions of composition NeuGc-Hex-HexNAc.
According to the fragmentation pattern observed in
the tandem mass spectrum of a glycan with precursor
ions at m/z 1200.4 (Figure 4a), the loss of 203 u, which
produced fragment ions at m/z 997.3 (B4) or 1015.3 (C4),
signalized HexNAc dehydrated form instead of the
usual residue with a reducing terminus. A small peak at
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, tumm/z 1038.3, which corresponded to the direct loss of
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m/z 569.2 consistent with Hex-(HexNAc)2 composition
residue, was highly correlated to the structure depicted
in Figure 4a.
Precursor ions at m/z 1362.5 (Figure 4b) lost addi-
tional 162 u (m/z 1200.4). For this oligosaccharide two
Figure 3. MALDI-MS/MS spectra of sialylated
tumor serum; (b) 2696.9 [M  H  2Na], heal
symbols see Figure 1.main structures were derived from MS/MS data. How-ever, ions at m/z 569.2 could be signed only to the
Isomer 2.
Oligosaccharide with precursor [M  H] ions de-
tected at m/z 2034.7 (Figure 4c) produced fragment ions
consistent with an additional NeuGc-Hex-HexNAc-Hex
residue (Y5 at 1727.7, Y4 at 1565.6, Y3 at 1362.5, Y2 at
ans recorded from (a) 2041.6 [M  H  2Na],
erum; (c) 3185.9 [M Na], healthy serum. Forglyc
thy s1200.4, Isomer 1). Fragment ions observed at m/z 1872.6,
. Co
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losses of neutral monosaccharide residues and could be
assigned to both Isomers 1 and 2, with two sialic acids
occupying only one antenna (Figure 4c). Here again, a
small ion peak at m/z 569.2 favored the Isomer 2. In the
MS/MS spectra of these glycoforms, relatively high
peaks observed at m/z 204.08 and lower, matched to
those observed in the tandem mass spectra recorded for
[M  H] ions of native and derivatized disaccharide
Gal(1-4)GlcNAc or in the study of per-O-methylated
protonated oligosaccharides [36].
Ion peaks detected at m/z 2016.7, 2162.8, 2345.9, and
2491.9 corresponded to labeled oligosaccharides in ad-
dition 60 u more (Table 2). For example, the [M  Na]
parent ions at m/z 2016.7 indicated a derivatized oligo-
saccharide, Hex5GlcNAc5PHN with an extra 60 Da
(before derivatization this oligosaccharides was de-
tected at m/z 1926.7). Based on the MS/MS fragmenta-
tion pattern, two isomers were suggested (Figure 5).
Characteristic fragments associated with the loss of
PHN-labeled reducing-terminal GlcNAc appeared at
m/z 1705.6 (B5) and 1518.5 (C4). Isomer 1 produced
distinctive ions at m/z 1077.4, indicating the loss of 60 u
from a GlcNAc residue at the 3-arm of the core man-
nose. The loss of GlcNAc and Hex residues produced
abundant ions at m/z 712.2 (B5/Y3), associated with the
loss of water (m/z 694.2). Abundant ions detected at m/z
Figure 3975.4 (B5/Y3) with the subsequent loss of water at m/z957.3 were consistent with Isomer 2. As discussed
above, the reducing GlcNAc residue was labeled with
phenylhydrazine and appeared as the loss of 311 u
followed by the loss of 203 u (overall the loss of
chitobiose core), the characteristic fragment ions ob-
served in the MS/MS spectra of all PHN-glycans. Thus
the 60 increment is part of or linked to a nonreducing
GlcNAc moiety on one antenna. The possibility of
incorporation of a mass 60 residue into a HexNAc
moiety (the existence of N-acetyl-octosamine, Scheme 1)
on the antenna of the core mannose can be supported
by other ions observed in Figure 5. Fragment ions
Table 2. Uncommon oligosaccharides detected in mice serum
Parent ion m/z
(observed)
Mr
(calculated) Composition (MALDI-MS/MS)
1200.4* 1199.4 Hex3 HexNAc2SA
1362.5* 1361.5 Hex4 HexNAc2SA
1565.6* 1564.6 Hex4 HexNAc3SA
1727.7* 1726.7 Hex5 HexNAc3SA
2034.7* 2033.7 Hex5 HexNAc3SA2
2016.7 1993.7 Hex5 HexNAc5PHN60
2162.8 2139.8 Hex5 HexNAc5FucPHN60
2345.9 2300.9 Hex5 HexNAc5SAPHN60
2491.9 2446.9 Hex5 HexNAc5 FucSAPHN60
*Ions observed corresponded to [M–H2OH]
.
 
ntinuedIons observed corresponded to [MNa] .
Ions observed corresponded to [M–H2Na].
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from the parent ion. Fragment ions that appeared as
relatively high peaks at m/z 414.1, 448.1, and 464.1 are
most probably associated with a Hex-GlcNAc(60)
residue (Scheme 1). These ions were not observed in the
MS/MS spectra of common N-linked oligosaccharides
(unpublished results).
To rule out the possibility that the above discussed
oligosaccharide structures with uncommon residue
were produced during sample preparation, other types
of treated or untreated samples were compared. In our
experience, commercial sources (e.g., bovine), glycop-
roteins (ovalbumin, transferrin, IgG) were digested,
treated, and fractionated under the same conditions
corresponding to those listed here in the experimental
part. Those other samples never showed the presence of
uncommon oligosaccharides forms. Also in our labora-
Figure 4. MALDI-MS/MS spectra and suggest
with the QqTOF mass spectrometer with [MH
(c) m/z 2034.7. The important fragment pathwa
emphasized by red color. Symbols: (filled ci
HexNAc(H2O); (filled diamond) NeuGc.tory, numerous experiments of derivatization withPHN show that the reagent did not cleave glycans or
monosaccharide units to small molecules. Those un-
usual oligosaccharides were already present in serum
before PHN and/or enzymatic treatment.
Distinctive Differences Observed in
Oligosaccharides from Serum Samples
The major distinction between oligosaccharides in se-
rum samples isolated from several tumoral and healthy
mice (representative example shown in Figure 1) was
the presence of high-mannose oligosaccharides, which
appeared as more abundant ions at m/z 1347, 1509, and
1671 in tumoral samples. Also, glycans with no GlcNAc
residue at the 6-positioned core mannose (hybrid gly-
cans, m/z at 1550.5, 1712.6, including not very common
ructure of glycans recorded from mouse serum
ecursor ions at: (a) m/z 1200.4, (b) m/z 1362.5, and
determination of the suggested structures are
Hex; (filled square) HexNAc; (open square)ed st
] pr
ys for
rcle)sialylated structure of m/z 2019.7) were detected only in
683J Am Soc Mass Spectrom 2008, 19, 671–685 N-LINKED OLIGOSACCHARIDES AND UNCOMMON GLYCOFORMthe sera obtained from mice with tumors. Precursor
ions at m/z 1712.7 were also detected in some healthy
samples. However, the MS/MS pattern did not indicate
an oligosaccharide composition. The higher occurrence
of high mannose and hybrid glycans in cancer sera
could support the hypothesis that tumor cell surface
glycoconjugates terminated by mannose or N-acetyl-
glucosamine residues are attacked by cells of the innate
immune network [37] and macrophages [38], which
have receptors for these carbohydrate residues.
N-glycans with a bisecting GlcNAc residue were
generally very minor in abundance and observed
mostly in the sera of tumoral mice. The same differ-
ences were observed in the study of sera of cirrhotic
patients [26]. Increased levels of 6-linked fucose are
often associated with cancer [25, 39]. In our study,
6-O-linked fucose residue on the reducing GlcNAc was
found in healthy and cancer samples, however in
higher abundances in cancer sera (at m/z 1899.7, 2228.7,
and 2557.8).
Complex sialylated N-glycans showed very similar
abundances in both types of serum. Only one major
difference was observed: disialylated fucosylated gly-
cans (m/z 2513.9 for [M  Na] ions, or 2557.8 for [M 
2H 3Na] ions), were considerably more abundant in
tumoral than in healthy samples.
The carbohydrates of uncommon composition (sia-
Figure 5. MALDI-MS/MS spectrum of a gly
QqTOF mass spectrometer for [MNa] precur
For symbols see Figure 1.lylated with dehydro-HexNAc residue in the end ofchain and those with the extra 60 units increment) were
detected in both type samples, however showed higher
abundances in control serum samples.
Conclusions
Serum samples were obtained from cancerous and
healthy mice and PNGase was used to release N-linked
glycans. A combination of PHN derivatization and
MALDI-MS was implicated in the analyses of these
glycans. The representative pools of labeled carbohy-
drates comprised more than 40 N-glycan structures of
high-mannose, hybrid, and complex compositions.
Asialo and sialylated oligosaccharides were analyzed
from the same spot. MALDI-MS/MS spectra provided
important insights towards the determination of struc-
tures of neutral and acidic glycans, and known struc-
ecorded from healthy mouse serum with the
ns at m/z 2016.7. All ions are sodium cationized.can r
sor ioScheme 1
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studies. The major differences between tumoral and
healthy sera were observed in the content of high-
mannose glycans and oligosaccharides without GlcNAc
linked on the 6-positioned mannose (hybrid glycans).
These glycans were distinctly more abundant in cancer
sera. Furthermore, in this study we did not observe
significant changes in the sialylation of complex oligo-
saccharides between cancerous and healthy sera.
Mostly all fucosylated glycans showed a 6-linked fucose
at the reducing termini in glycans of both serum types,
however with higher abundances of these oligosaccha-
rides in cancerous serum.
The present study further confirms the presence of
oligosaccharides with uncommon compositions. Sev-
eral sialylated dehydrated oligosaccharides with no free
reducing end in the chain were detected in the sera. In
spite of MS/MS fragmentation patterns isobaric for
more possible structures, a few small ion peaks were
critical to assign the suggested structures. Biantennary
glycans with extra 60 units seem to bear a 2-acetamido-
2-deoxyoctose residue linked to a nonreducing man-
nose in biantennary glycans. Confirmation of these
uncommon glycans by other analytical methods was
not possible due to their low abundances in the sample
analyzed. Nonetheless, the consistent and reproducible
MS/MS data provided a good level of confidence for
the presence of these structures. In addition, the com-
parison of fragmentation patterns of uncommon struc-
tures with those of known glycans, analyzed in both
native and derivatized forms, gave a good basis to
suggest the novel glycoforms observed in this study.
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